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Markedly improved outcomes and acceptable toxicity in
adolescents and young adults with acute lymphoblastic
leukemia following treatment with a pediatric protocol: a
phase II study by the Japan Adult Leukemia Study Group
F Hayakawa1, T Sakura2, T Yujiri3, E Kondo4, K Fujimaki5, O Sasaki6, J Miyatake7, H Handa8, Y Ueda9, Y Aoyama10, S Takada2, Y Tanaka3,
N Usui11, S Miyawaki12, S Suenobu13, K Horibe14, H Kiyoi1, K Ohnishi15, Y Miyazaki16, S Ohtake17, Y Kobayashi18, K Matsuo19
and T Naoe20 for the Japan Adult Leukemia Study Group (JALSG)
The superiority of the pediatric protocol for adolescents with acute lymphoblastic leukemia (ALL) has already been demonstrated,
however, its efficacy in young adults remains unclear. The ALL202-U protocol was conducted to examine the efficacy and feasibility
of a pediatric protocol in adolescents and young adults (AYAs) with BCR–ABL-negative ALL. Patients aged 15–24 years (n= 139)
were treated with the same protocol used for pediatric B-ALL. The primary objective of this study was to assess the disease-free
survival (DFS) rate and its secondary aims were to assess toxicity, the complete remission (CR) rate and the overall survival (OS) rate.
The CR rate was 94%. The 5-year DFS and OS rates were 67% (95% confidence interval (CI) 58–75%) and 73% (95% CI 64–80%),
respectively. Severe adverse events were observed at a frequency that was similar to or lower than that in children treated with the
same protocol. Only insufficient maintenance therapy significantly worsened the DFS (hazard ratio 5.60, Po0.001). These results
indicate that this protocol may be a feasible and highly effective treatment for AYA with BCR–ABL-negative ALL.
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INTRODUCTION
Acute lymphoblastic leukemia (ALL) has been very successfully
treated in children, however, the prognosis of patients markedly
deteriorates from the onset of adolescence to adulthood. A period
analysis of ALL patients between 2000 and 2004 showed 5-year
relative survival rates of 80.7% in patients aged 10–14 years and
44.8% in patients aged 20–29 years.1,2 Retrospective studies that
focused on patients aged 15–21 years reported that adolescents
and young adults (AYAs) treated with adult ALL protocols had
poorer outcomes than similarly aged patients treated with
pediatric protocols.3–6 However, these studies compared patients
treated with a pediatric protocol by pediatricians to those treated
with an adult protocol by physicians; the former were adolescents
with a median age of 16 or 17 and the latter were AYAs with a
median age 19 or older. These findings were similar to those of
recently reported prospective studies by pediatric groups.7,8 The
reason of the efficacy of pediatric protocols on young adults and
how the difference in age between these patient groups is
responsible for the observed differences in survival have yet to be
determined, and can only be clarified by examining patients
treated with pediatric protocols in an adult study group. Several
prospective clinical trials using pediatric regimens for adults are
currently ongoing. These studies have been divided into two types
based on their regimens and patients: a pediatric-inspired
protocol with dose reductions in a pediatric protocol for adults
up to 60 years, and an unmodified pediatric protocol for AYA up to
30 years. A few of the former studies have already been
completed, and the results obtained revealed marked improve-
ments in the survival rates of ALL patients up to 60 years old.9,10
However, the possibility that AYA may achieve better survival rates
with the original pediatric protocol was not investigated in these
studies. The feasibility and efficacy of an unmodified pediatric
protocol for AYA should be examined. One previous study
reported marked improvements in survival rates;11 however, only
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standard-risk ALL were treated. Therefore, the efficacy of this
protocol in young adults with high-risk ALL remains unknown.
The Japan Adult Leukemia Study Group (JALSG) conducted a
phase 2 trial in which patients aged 15–24 years with BCR–ABL-
negative ALL were treated with the same protocol developed for
children with ALL by the Japan Association of Childhood Leukemia
Study (JACLS). We analyzed the outcomes and prognostic factors
of the 139 AYA patients treated in this trial.
PATIENTS AND METHODS
Patients and eligibility criteria
The JALSG ALL202-U (ALL202-U) study is a prospective nonrandomized
phase 2 trial, a part of the JALSG ALL202 (ALL202) study conducted by
JALSG and was registered at UMIN-CTR (ID: C000000064). Eligibility criteria
were common with the ALL202 study.12 The protocol was approved by the
Institutional Review Board of each hospital. Written informed consent was
obtained from all patients before registration in accordance with the
Declaration of Helsinki. Guardians also gave written informed consent
when patients were under 20 years old. The study was initiated in August
2002 and closed for patient inclusion in October 2009.
Diagnostic procedure
ALL was diagnosed according to the French–American–British
classification13 using morphology, cytochemistry and immunophenotyping
studies at each institution. Mature B-cell ALL was excluded. Immunophe-
notyping and cytogenetic studies were performed as described
previously.14 The multiplex reverse transcription-PCR test was described
previously.12
Study design and treatment
The study design of ALL202 has previously been described in detail.12
Patients were treated differently according to age and the BCR–ABL
diagnosis results. Patients aged 15–24 years and negative for BCR–ABL
were treated with the same pediatric regimen as the ALL202-U study. The
protocol was conducted for high-risk pediatric B-ALL in the ALL-02 study
by the JACLS and designated as ALL-02-HR.15 The study was initiated in
April 2002, closed for patient inclusion in May 2008 and the results are
awaited. The toxicity data of this study, which have been referred later,
were obtained by analysis in May 2011.
The treatment schedule for ALL202-U is shown in Table 1. Patients
underwent a 7-day prephase therapy with prednisolone (PSL) and a single
intrathecal injection of methotrexate (MTX) after registration. Responsive-
ness to PSL was judged on day 8, and BCR–ABL-negative patients
continued the protocol study. Patients who achieved complete remission
(CR) after induction therapy received consolidation therapy, sanctuary
therapy, reinduction therapy and reconsolidation therapy. Patients who
did not achieve CR after induction therapy received consolidation therapy.
If CR was not achieved with this therapy, protocol therapy was terminated
as induction failure.
Allo-stem cell transplantation (SCT) was recommended for patients with
t(4;11) who achieved CR during their first CR if a human leukocyte antigen-
matched sibling was available, and allo-SCT from an alternative donor was
allowed. An indication for SCT was decided for patients with other types
according to institutional discretion. Each institution decided the
preparative and post-transplant regimens for SCT according to its own
discretion.
Detailed rules for treatment
Every therapy had a planned therapy duration. New therapy was started on
the planned day if neutrophil and platelet counts had reached ⩾ 0.5 × 109/l
and ⩾ 50× 109/l, respectively, and patients had no significant infection at
that time. Therapies could be started earlier if patients fulfilled the above
conditions. Delays within 3 days for social reasons and 4 weeks because of
complications were allowed. Folic acid rescue in sanctuary therapy was
increased to every 3 h when the blood concentration of MTX was ⩾ 1.0
μmol/l 48 h after its administration or ⩾ 0.2 μmol/l after 72 h, and was
continued until the MTX concentration fell to o0.1 μmol/l. When the MTX
concentration was ⩾ 0.1 μmol/l and o0.2 μmol after 72 h, folic acid rescue
was added only four times every 6 h. Maintenance therapy consisted of 16
courses of therapy. The dose of 6-MP was adjusted to maintain the white
blood cell (WBC) count at 2–3× 109/l. Central nervous system (CNS)
prophylaxis included the administration of 14 courses of intrathecal
therapy of MTX, cytarabine and hydrocortisone and a single intrathecal
injection of MTX.
Evaluation of patients
CR was defined as the presence of all of the following: o5% blasts in bone
marrow, no leukemic blasts in peripheral blood, recovery of peripheral blood
values to neutrophil counts of at least 1.0×109/l and platelet counts of at least
100×109/l, and no evidence of extramedullary leukemia. Relapse was defined
as the presence of at least one of the following: recurrence of410% leukemic
cells in bone marrow or any leukemic cells in peripheral blood or
extramedullary sites. Toxicity was evaluated based on the National Cancer
Institute Common Toxicity Criteria (NCI-CTC) Version 2.0 (http://ctep.cancer.
gov/protocolDevelopment/electronic_applications/docs/ctcv20_4-30-992.pdf).
Corticosteroid sensitivity was defined as a peripheral blood blast cell count
o1.5×109/l after the 7-day corticosteroid prephase.
Sample size estimation and statistical analysis
This study was designed as phase 2 and the sample size was determined
before the study. We set an expected 5-year disease-free survival (DFS) rate
of 50%, and estimated that 96 patients were required to achieve a 95%
confidence interval (CI) of narrower than ± 10%. Considering potential
dropout because of ineligibility or loss to follow-up, we finally used 120 as
the required number of patients.
The primary objective of this study was to assess DFS rate, and the
secondary aims were to assess toxicity, the CR rate and the overall survival
(OS) rate. An exploratory evaluation of potential prognostic factors was
also conducted. We defined DFS as the time from the date of achieving CR
to relapse, death or the last visit, and OS as the time from the first day of
therapy to death or the last visit. Patients undergoing SCT were not
censored at the time of transplantation and were evaluated with the
inclusion of a post-transplantation period. The results for Ph-negative ALL
patients under 25 years old in the JALSG ALL97 study (ALL97-U) were used
as a reference. The treatment schedule for ALL97 has been reported
previously14 and was shown in Supplementary Table 1. The Χ2 test was
used to statistically analyze characteristic differences between patient
groups. The Kaplan–Meier product limit method was performed to
estimate DFS and OS. Patients were divided into two groups in some
analyses. Patients whose WBC counts were o30× 109/l and karyotype
risks that were standard or intermediate in the modified MRC UKALLXII/
ECOG E2993ALL cytogenetic classification16 were defined as the standard-
risk group, and others were defined as the high-risk group. The DFS rates
of each group were analyzed separately. To compare DFS and OS rates, the
log-rank test was used for univariate analysis, and a Cox proportional
hazard model for uni- and multivariate analyses. To evaluate maintenance
therapy insufficiency, we treated the termination of maintenance therapy
as a time-varying covariate. Stata SE 11.2 (Stata Co., College Station, TX,
USA) was used for all statistical analyses.
RESULTS
Patient entry and characteristics
Between August 2002 and October 2009, 150 patients from 59
hospitals participating in the JALSG were enrolled in this study.
Eleven patients were excluded because two had been misdiag-
nosed (one with acute myeloid leukemia and one with BCR–ABL-
positive ALL), four had dropped out before starting the treatment,
four had been registered after prephase therapy and one was
registered before protocol approval by the Institutional Review
Board. Therefore, we here reported the outcomes of 139 eligible
patients. The diagnosis of BCR–ABL negativity was based on the
Multiplex RQ-PCR assay (n= 124), BCR–ABL RQ-PCR assay (n= 1),
fluorescent in situ hybridization analysis (n= 7) and chromosome
karyotype assay (n= 7). The pretreatment characteristics of
ALL202-U and ALL97-U were summarized in Table 2. The median
age was 19 years and there were 78 men (56%) and 61 women.
Cytogenetic evaluations were performed in all 139 patients, and
revealed that all were Ph-negative. Results were classified
according to the modified MRC UKALLXII/ECOG E2993ALL
cytogenetic subgroups:16 the very high-risk group (n= 15)
included t(4;11), complex karyotype, defined as 45 abnormalities
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without known translocations or low hypodiploidy/near triploidy;
the high-risk group (n= 8) included other MLL translocations,
monosomy 7 with o5 abnormalities or t(1;19); the intermediate-
risk group (n= 110) included a normal karyotype or other
miscellaneous abnormal karyotypes; the standard-risk group
(n= 2) included high hyperdiploidy. The multiplex RQ-PCR assay
Table 1. JALSG-ALL202-U schedule
Phases/drugs Route Doses Days
Induction therapy (weeks 1–5)
Methotrexate IT 12mg/body 1
Prednisolone PO/IV 60mg/m2 1–7
Dexamethasone IV 10mg/m2 8–14
Vincristine IV 1.5 mg/m2 a 8, 15, 22, 29
THP-adriamycin IV 25mg/m2 8, 9
Cyclophosphamide IV 1200mg/m2 10
L-asparaginase IV/IM 6000 U/m2 15, 17, 19, 21, 23, 25, 27, 29
Prednisolone PO 40mg/m2 15–28
IT-tripleb IT 8, 22c
Consolidation thrapy (weeks 6–9)
Cyclophosphamide IV 750mg/m2 1, 8
THP-adriamycin IV 25mg/m2 1, 2
Cytarabine IV 75mg/body 1–6, 8–13d
Mercaptopurine PO 50mg/m2 1–14
IT-tripleb IT 1, 8
Sanctuary therapy (weeks 10–11)
Methotrexatee IV (24 h) 3 g/m2 1, 8
IT-tripleb IT 2, 9
Reinduction therapy (weeks 12–15)
Vincristine IV 1.5 mg/m2 a 1, 8, 15
THP-adriamycin IV 25mg/m2 1, 8
Cyclophosphamide IV 500mg/m2 1, 8
L-asparaginase IM 6000 U/m2 1, 3, 5, 8, 10, 12
Prednisolone PO 40mg/m2 1–14
IT-tripleb IT 1
Reconsolidation therapy (weeks 16–19)
Same as consolidation therapy
Maintenance therapy 1-A (weeks 20–25) for CNS-invasion-negative cases
Methotrexate IV 150mg/m2 1, 15, 29
Mercaptopurine PO 50mg/m2 f 1–28
IT-tripleb IT 29
Maintenance therapy 1-B (weeks 20–25) for CNS-invasion-positive cases
Cranial irradiation 1.5 Gry × 8 1–12g
Methotrexate IV 150mg/m2 29
Mercaptopurine PO 50mg/m2 f 1–28
IT-tripleb IT 1, 8
Maintenance therapy 2 (weeks 26–29, 46–49, 66–69, 86–89)
Vincristine IV 1.5 mg/m2 a 1, 8, 15
Cyclophosphamide IV 600mg/m2 8
L-asparaginase IM 10 000 U/m2 1, 8, 15
Prednisolone PO 40mg/m2 1–14
Maintenance therapy 3 (weeks 30–35, 40–45, 50–55, 60–65, 70–75, 80–85, 90–95)
Methotrexate IV 150mg/m2 1, 15, 29
Mercaptopurine PO 50mg/m2 f 1–28
IT-tripleb IT 29h,i
Maintenance therapy 4 (weeks 36–39, 56–59, 76–79, 96–98)
Vincristine IV 1.5 mg/m2 a 1, 8, 15
THP-adriamycin IV 25mg/m2 8
L-asparaginase IM 10 000 U/m2 1, 8, 15
Prednisolone PO 40mg/m2 1–14
Abbreviations: CNS, central nervous system; JALSG, Japan Adult Leukemia Study Group; IM, intramuscularly; IT, intrathecally; IV, intravenously; PO, per os; WBC,
while blood cell. aMaximum dose was 2mg per body. bIT-triple consisted of methotrexate 12 mg, cytarabine 30mg and hydrocortisone 25mg. cOn days 8, 11,
15, and 22, when CNS invasion was positive. dAdministration was stopped, when neutrophil count went down to 0/l. eWith folinic acid rescue (15mg/m2, IV, six
times every 6 h), beginning 42 h after the start of methotrexate infusion. fDose should be adjusted to keep WBC count from 2000 to 3000/ul. gEight times
during this period. hFor CNS-invasion-negative cases. iNot on weeks 74 and 94.
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was performed for 124 patients. Twelve sets of primers were used
to detect WT1, MDR1, and nine distinct fusion gene transcripts,
namely, major and minor BCR–ABL, TEL-AML1, E2A-PBX1, MLL-AF4,
MLL-AF6, MLL-AF9, MLL-ENL, SIL-TAL1 and GAPDH as an internal
control. One hundred eight samples were analyzed by the full set
of primers, eight samples by primers not including MDR1 and
eight samples by primers not including MDR1, MLL-ENL and SIL-
TAL1. Six patients were positive for E2A-PBX1, two for TEL-AML1,
one for MLL-AF4 and one for MLL-ENL. ALL patients were negative
for MLL-AF6 and MLL-AF9.
Response to induction therapy
The results of therapy are summarized in Supplementary Table 2.
A total of 130 (94% (95% CI 88–97%)) of 139 evaluated patients
achieved CR: 124 after the first treatment and 6 after the second
course. Four patients died of sepsis during the first induction
therapy before their remission status could be ascertained, and
these were the only deaths that occurred during induction
therapy. Three patients failed to achieve CR after two courses of
therapy. Two patients dropped out of the study without starting
the second therapy, because the first therapy failed to achieve CR.
These results were markedly better than ALL97-U. The CR rate was
84% (95% CI 75–90%) and 12 patients died during induction
therapy in ALL97-U.
Survival
Nine out of 139 eligible patients did not achieve CR and 7 of them
died. Of the 130 CR patients, 5 patients died in remission, 1 died
for an unknown reason and 34 patients relapsed; 19 of them
received SCT and 23 relapsed patients died. A total of 36 patients
died (Figure 1a). The estimated 5-year DFS rate was 67% (95% CI
58–75%, Figure 1b) and the estimated probability of the OS rate at
Table 2. Patient characteristics
Characteristics ALL202-U (n=139) ALL97a (n= 104) P-value
No. (%) No. (%)
Sex
Male 78 (56) 58 (56)
Female 61 (44) 46 (44) 0.957
Age
Median 19 19
Age o20 83 (60) 54 (52)
Age ⩾ 20 56 (40) 50 (48) 0.226
PS
0–1 128 (92) 93 (89)
2–4 11 (8) 11 (11) 0.474
WBC count (/μl)
Median 10 500 11 480
WBC o50 000 104 (75) 79 (76)
WBC ⩾ 50 000 35 (25) 25 (24) 0.838
Serum LDH level
Normal 20 (14) 14 (13)
Elevated 119 (86) 90 (87) 0.415
Phenotype
CD19+, CD10- 18 (13) 20 (19)
CD10+ 89 (64) 69 (66)
CD19− , CD7+ 31 (22) 14 (14) 0.591b
Unknown 1 (1) 1 (1)
Karyotypec
Standard risk 2 (1) 5 (5)
Intermediate risk 110 (79) 74 (71)
High risk 11 (8) 7 (7)
Very high risk 15 (11) 7 (7) 0.322b
Unknown 1 (1) 11 (10)
Chimera mRNA
E2A-PBX1 6 (5)
SIL-TAL1 4 (3)
TEL-AML1 2 (2)
MLL-AF4 1 (1)
MLL-ENL 1 (1)
CNS involvement
Negative 128 (95) 103 (99)
Positive 7 (5) 1 (1) 0.072
Abbreviations: CNS, central nervous system; LDH, lactic acid dehydrogenase;
PS, performance status; WBC, white blood cell. aPh-negative patients under
25 years were extracted. bAnalyzed excluding unknown cases. cModified
MRC UKALLXII/ECOG E2993ALL cytogenetic subgroups.
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Figure 1. Comparison of DFS and OS rates. (a) Patient flow chart.
(b) Comparison of DFS rates between ALL202-U (red line) and
ALL97-U (blue line). The median follow-up times were 5.1 and 5.2
years, respectively. (c) Comparison of OS rates between ALL202-U
(red line) and ALL97-U (blue line). The median follow-up times were
5.1 and 5.8 years, respectively.
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5 years was 73% (95% CI 64–80%; Figure 1c). Both the DFS rate
and OS rate were markedly better than those of ALL97-U patients
(44 and 45%, respectively; Figures 1b and c).
The results of univariate analysis on the effects of clinical and
biological features on the DFS rate are summarized in Figure 2 as a
forest plot. Age, performance status, CNS involvement, WBC
counts, immunophenotype, cytogenetics, PSL response and CR
achievement by the second induction therapy did not correlate
with DFS.
We stratified patients with widely accepted risk factors, WBC
counts and karyotypes as described in the Patients and Methods
section, and analyzed survival in each group. Sixty-nine and 61
patients in ALL202-U were classified into the standard-risk group
and high-risk group, respectively, and 50 and 28 patients in ALL97-
U were classified in a similar manner. The DFS rate of ALL202-U
patients was markedly better than that of ALL97-U patients both
in the standard-risk group (71% vs 54%) and high-risk group (63%
vs 28%; Figures 3a and b). As a result, no significant difference was
observed in the DFS rate between the standard-risk and high-risk
groups in ALL202-U (71% vs 63%, P= 0.4291; compare red lines in
Figures 3a and b), however, it was significant in ALL97-U (54% vs
28%, P= 0.0053; compare blue lines in Figures 3a and b).
Some patient groups with possible poor prognostic factors,
such as severe leukocytosis, pro-B and T-cell phenotypes, and
poor PSL responses, contained more patients who received SCT in
the first remission (Supplementary Table 3), which suggested that
good survival outcome of ALL202-U was the result of the rescue of
high-risk patients by SCT, however, no significant difference was
observed in the DFS rate between patients that received SCT and
those who did not, even in the high-risk group (Supplementary
Figures 1A and B). These results suggested that the effect of the
possible rescue of high-risk patients by SCT, if any, was not
marked.
Toxicity
A full assessment of toxicity was performed in 1688 courses of
chemotherapy (139 induction therapies, 126 consolidation thera-
pies, 113 sanctuary therapies, 102 reinduction therapies, 98
reconsolidation therapies and 1110 maintenance therapies).
Ninety-nine percent of patients developed grade 4 neutropenia
during induction therapy, however, it was difficult to distinguish
this from hematopoietic disorders by leukemia. The grade 3–4
adverse events observed during induction therapy were as
follows: febrile neutropenia, sepsis and other infections occurred
in 46.5%, 15% and 4.4% of patients, respectively. Elevated alanine
aminotransferase levels, pancreatitis and ileus were observed in
27.8%, 6.6% and 3.6%, respectively. Eighteen (13.2%) and 10
(7.2%) patients developed disseminated intravascular coagulo-
pathy and gastrointestinal bleeding, respectively. Hyperglycemia,
neuropathy and tumor lysis syndrome occurred in 4.4%, 3.6% and
3.6%, respectively. Diarrhea, heart disease, creatinine elevations
0 20 40 60 80 100 
Disease-free survival rate (%) 
CNS inv (-) (128)
CNS inv (+) (7)
WBC50000 (104)
PS2 (128)
Age20 (83)
WBC ≥ 50000 (35) 
PS ≥2 (11)
Age ≥ 20 (56)
CD19+CD10-  (18)
CD10+ (89)
CD19-CD7+ (31)
Karyotype St + Int (112)
Karyotype H + VH (26)
Good PSL response (95)
Poor PSL response (39)
Total (139)
Subgroup (Number of patients)
CR by 2nd induction (6)
CR by 1st induction (124)
0.8511
0.7456
0.8894
0.1415
0.732
0.296
0.2226
p value
0.6331
Figure 2. Forest plot of subgroup analysis for DFS rates. 5-year DFS rate of each subgroup was calculated and compared by the log-rank test.
Patients undergoing transplantation were not censored. The 5-year DFS rate with 95% CIs are plotted and P-values of the log-rank test are
shown. Numbers following subgroup names indicate the number of cases in the groups.
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and brain bleeding were observed in o1% of patients.
Severe adverse events such as neutropenia, thrombocytopenia,
febrile neutropenia, sepsis, hepatic toxicity, pancreatitis and
neuropathy occurred frequently during post-remission therapy.
These have been summarized in Table 3. Toxicity was evaluated in
the ALL97 study with the toxicity grading criteria of the Japan
Clinical Oncology Group (JCOG). ALL202-U results were compared
with those of ALL97-U in the points where the criteria coincided
between NCI-CTC version 2 and the JCOG (Table 3). Sepsis, hepatic
toxicity and neuropathy were more frequent in ALL202-U,
although no patient died from the adverse events associated
with chemotherapy during post-remission therapy in this study. In
the pediatric study, JACLS ALL-02, patients in the high-risk group
were treated with the ALL-02 HR protocol, which was the same as
JALSG ALL202-U; 136 patients aged 10–18 years (90% patients
were o15 years old) were treated with ALL-02 HR. Severe adverse
events, except for pancreatitis, occurred more frequently in
pediatric patients (Table 3).
Protocol adherence
Therapies were delayed in many patients, and this was attributed
to the adverse events associated with chemotherapy, however,
some patients could proceed to the next therapy earlier than
planned. The median delays from the planned schedule were 7
(range 0 to 171), 7 (range − 9 to 35), 9 (range 0 to 36), 6 (range − 8
to 70) and 19 (range − 5 to 62) days in induction, consolidation,
sanctuary, reinduction and reconsolidation therapy, respectively.
As for the 57 patients who completed maintenance therapy,
the median duration of maintenance therapy was 633 (range
553–881) days, which was 80 (range 0–328) days more than the
planned schedule. No patients could complete the whole therapy
without delays.
L-asparaginase dose reductions were required for 48 (35%), 18
(18%) and 38 (47%) patients because of its adverse events in
induction, reinduction and maintenance therapy, respectively.
Seventeen (30%) patients could complete the whole therapy
without dose reductions in any drugs.
Fifty-seven (41%) patients could complete the whole therapy
and 81 (59%) dropped out of the protocol therapy. The reasons,
frequencies and periods of protocol therapy terminations have
been summarized in Figures 4a and b. Seven (6%) patients were
primary refractory, including early death, and 12 (9%) relapsed.
Thirty-one (22%) patients dropped out of the study in the first
remission to receive SCT. Twenty-two (16%) patients terminated
protocol therapy because of severe adverse events. Eight (6%)
patients dropped out of the study for their own reasons. One (1%)
patient received the same maintenance therapy as ALL97 because
of a doctor's mistake. This case was treated as a dropout because
of a protocol violation. A significantly large number of patients
dropped out after reconsolidation therapy for reasons other than
relapse and SCT, and subsequently received no or insufficient
maintenance therapy. In order to analyze the effects of insufficient
maintenance therapy on survival, patients who achieved CR were
divided into four groups: patients who did not drop out for
reasons other than relapse (patients received planned post-
remission therapy), those who dropped out because of SCT
(patients received SCT in first CR) and those who dropped out for
reasons other than relapse and SCT before and after the
completion of drug administration in reconsolidation therapy
(patients received insufficient consolidation therapy and patients
received insufficient maintenance therapy, respectively). The
estimated 5-year DFS rates of these groups were 76% (95% CI
63–84%), 70% (95% CI 50–83%), 29% (95% CI 5–59%) and 45%
(95% CI 19–68%), respectively (Figure 4c). The DFS rate of patients
who received insufficient maintenance therapy was compared
with others using a proportional hazard model with time-varying
covariates. The hazard ratio of insufficient maintenance therapy
was 5.59 (95% CI 2.52–12.41, Po0.001) in univariate analysis and
5.60 (95% CI 2.36–13.26, Po0.001) in multivariate analysis
(Table 4).
DISCUSSION
The results of this prospective study indicate that the pediatric
protocol, ALL202-U, enabled markedly better survival rates to be
achieved by AYA with ALL than the conventional adult protocol,
ALL97. The OS rate reported here was similar to those reported in
previous retrospective studies: 78% (age 15–20),3 71% (age 15–
17),4 79% (age 15–18)6 and 67% (age 16–20). 5 It was also similar
to previous prospective studies by two pediatric groups (81% in
those aged 15–18 years and 78% in those aged 16–21 years)7,8
and an adult group (6-year OS rate for standard-risk ALL patients:
69% in those aged 15–30 years).11 Patients who received the
pediatric protocol treatment were mainly adolescents and 480%
were 18 years and under in all retrospective studies and
prospective studies by pediatric groups.7,8 Regardless of the
prospective or retrospective design, comparisons with pediatric
group studies could not conclude the efficacy of the pediatric
protocol in young adults, however, the only study of an adult
group included only standard-risk ALL patients (WBC count
⩽ 30 × 109/l, and absence of t(9;22), t(1;19), t(4;11) or any other
11q23 rearrangements).11 Ours is the only study on whole Ph-
negative AYA ALL that used an unmodified pediatric protocol. The
results obtained in our study demonstrated for the first time that a
pediatric protocol was feasible and could also markedly improve
survival in Ph-negative high-risk young adult ALL patients.
Concerning the key difference between pediatric protocols
and adult protocols, pediatric protocols use more non-
myelosuppressive drugs, such as glucocorticoids and L-asparagi-
nase and fewer myelosuppressive drugs, such as anthracycline,5
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Figure 3. Comparison of the DFS rate in each risk group.
(a) Comparison between ALL202-U standard-risk (SR) patients (red
line) and ALL97-U SR patients (blue line). (b) Comparison between
ALL202-U high-risk (HR) patients (red line) and ALL97-U HR patients
(blue line).
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which was applied to the comparison between ALL202-U and
ALL97. Many differences existed between these two protocols,
such as the cumulative doses and dose intensities of each drug,
treatment durations and prophylaxis of CNS involvement; there-
fore, we cannot identify the key difference responsible for the
different treatment outcomes by comparing the whole protocols.
However, this comparison becomes simple by focusing on
induction therapy. The treatment schedules were similar between
the protocols, except that ALL202-U had three treatments with
intrathecal injections and prephase therapy of PSL for 7 days.
Therefore, marked differences were observed in the cumulative
doses. The main difference noted was that ALL202-U used more
L-asparaginase (48 000 vs 18 000 U/m2) and glucocorticoids
(980 mg/m2 PSL and 70mg/m2 dexamethasone vs 840mg/m2
PSL) and less anthracycline (50 mg/m2 THP-adriamycin vs 135 mg/
m2 daunorubicin). Owing to the upper limit of the dose (2 mg per
body), the planned cumulative doses of vincristine were almost
identical (8.0 vs 7.8 mg per body). Therefore, these differences
have been implicated in the marked difference observed in the CR
rate of the first induction therapy (89.2% vs 76.0%), which
suggests that the increased doses of L-asparaginase and
glucocorticoids partly contributed to the improved survival in
the ALL202-U study.
The indication for allo-SCT in the first remission remains a
controversial issue in ALL. SCT is currently recommended in Japan
in the first remission for high-risk ALL, defined by WBC 430× 109/
l, a high-risk karyotype such as t(9;22), t(4;11), t(1;19), and +8, age
⩾ 30, or late CR achievement. Therefore, it was unavoidable that
unignorable number of patients received allo-SCT, which made
the interpretation of the results of this study difficult, however,
SCT did not affect the DFS rate in multivariate analysis (hazard
ratio 1.01; Table 3) and did not improve the DFS rate of ALL202-U
patients, even in the high-risk group (P= 0.9394; Supplementary
Figures 1A and B). Therefore, the superiority of ALL202-U to
historical control was not impaired. Based on the good outcomes
observed in this study, SCT will no longer be recommended in the
first remission for this type of high-risk ALL of AYA if patients are
treated by this protocol. The indication for SCT in the first
remission for ALL of AYA should be similar to that for pediatric
patients. Children with Ph-negative ALL in Japan are recom-
mended to receive SCT in the first remission if they are positive for
Table 3. Comparison of adverse effect
ALL202-U vs ALL97
Therapy G4 neutropenia (%) G3-G4
thrombocytopenia (%)
Sepsis (%) G3-G4 hepatic
toxicity (%)
G3-G4
neuropathy (%)
ALL202-U (age 15–24)
Induction 15 27.8 3.6
Consolidation 99.2 97.8 7.4 13.5 2.4
Sancturary 12 19.7 2.6 13.2 1.8
Reinduction 65 42.6 3.9 16.7 0
Reconsolidation 99 100 9.1 5.1 4
ALL97 (age 15–24)
Induction 3.8 11.2 0
C1 73.7 10.5 0 4.2 0
C2 61.7 9.9 0 0 0
C3 64.6 3.8 0 0 0
C4 97.1 97.1 0 0 0
C5 41.9 1.6 0 0 0
C6 58.9 25 0 0 0
C7 86.8 9.4 0 0 0
C8 98 100 2.2 0 0
AYA vs pediatrics
Therapy Febrile
neutropenia (%)
G3-G4
pancreatitis (%)
G4 hepatic
toxicity (%)
G3-G4 neuropathy (%)
ALL202-U (age 15–24)
Induction 46.5 6.6 1.0 3.6
Consolidation 44.4 0.0 0.0 2.4
Sancturary 9.7 0.0 0.0 1.8
Reinduction 25.5 5.8 1.0 0.0
Reconsolidation 55.6 0.0 0.0 4.0
Maintenance 0.8 0.3 0.3 0.2
ALL-02-HR (age 10–18)
Induction 63.9 5.0 3.4 9.3
Consolidation 58.0 1.1 3.5 6.5
Sancturary 37.8 0.0 0.0 13.3
Reinduction 51.8 1.1 1.1 3.3
Reconsolidation 73.7 0.0 0.0 0.0
Maintenance 8.5 0.3 0.6 0.2
Abbreviation: AYA, adolescent and young adult.
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the chromosome 11q23 abnormality, show a poor PSL response,
or achieve CR later than 6 weeks from the treatment start.
A poor PSL response was previously shown to be a stronger
prognostic factor than age and the WBC count in pediatric
B-ALL.17,18 The JACLS ALL-02 study and other pediatric studies
used the PSL response for risk stratification. In our study, a poor
PSL response did not significantly worsen the prognosis of
patients (Figure 2). Patients with a poor PSL response received SCT
during the first remission more frequently than those with a good
PSL response (33% vs 22%; Supplementary Table 3), and 22% of
patients had T-ALL in this study (Table 2). These results should be
considered, however, a poor PSL response was not a significant
risk factor in multivariate analysis (Table 4). The prognostic impact
of the PSL response should be investigated in a larger number of
patients. Considering the rarity of ALL in AYA, this should be
examined in patients with a wider age range. Among other
patient characteristics and therapy responses, the risks of late CR
achievement and presence of t(4;11), other 11q23 rearrangements
and t(1;19) could not be determined in this study because of the
small number of patients (6, 1, 1 and 6, respectively) and high
frequency of receiving SCT (50%, 100%, 0% and 67%, respectively).
The toxicity of the ALL202-U protocol appeared to be high
because severe adverse events occurred more frequently in this
study, however, the death rate during induction therapy was lower
in this study than ALL97 (3% vs 12%; Supplementary Table 2),
and this may have been because patients achieved CR more
frequently and quickly in this study. In addition, no chemotherapy-
related deaths were observed during post-remission therapy in
this study. These results indicate the tolerability of this protocol by
AYA. Children treated with the same protocol in the JACLS ALL-02
study exhibited severe adverse events more frequently than AYA
in this study. Our results indicated that AYA tolerated chemother-
apy better than children, except for L-asparaginase-induced
pancreatitis. These results suggested that ALL202-U was feasible
as a treatment for AYA with BCR–ABL-negative ALL.
Adherence to the protocol was not good in this study, and this
was mainly due to the high toxicity of this treatment. Protocol
therapy was frequently terminated because of adverse events and
the patients' wishes. Such therapy terminations were the most
frequent during maintenance therapy (Figure 4b), although the
frequency of severe adverse events was markedly less during
maintenance therapy than all other post-remission therapies
(Table 3). This result suggested maintenance therapy may have
been terminated because of less severe adverse events. Another
reason is the difficulty in maintaining motivation for therapy in AYA
against their psychosocial conditions. Our results clearly showed the
significant importance of completing maintenance therapy. This
information will help to maintain motivation for therapy, and may
lead to further improvements in the outcomes of patients.
Taken together, ALL202-U caused high, but acceptable toxicity
and led to a markedly better outcome than the previous study and
is thought to be a feasible and highly effective treatment for AYA
with BCR–ABL-negative ALL, including high-risk cases.
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Figure 4. Analysis of protocol therapy termination. (a) The reasons
for and frequencies of protocol therapy termination. (b) The periods
of and reasons for protocol therapy termination. (c) The effect of
therapy insufficiency on the DFS rate. DFS rates were compared
among groups of patients who received planned post-remission
therapy (blue line), those who received SCT in first CR (green line),
those who received insufficient consolidation therapy (yellow line)
and those who received insufficient maintenance therapy (red line).
Table 4. Multivariate analysis of the effect of biological and clinical
features on DFS
Parameters Hazard ratio (95% CI) P-value
Insufficient maintenance therapy 5.60 (2.36–13.26) o0.001
Age ⩾ 20 1.25 (0.62–2.52) 0.531
PS ⩾ 2 1.28 (0.42–3.91) 0.662
CNS involvement (+) 0.93 (0.19–4.50) 0.927
WBC ⩾ 50000 1.63 (0.77–3.43) 0.195
Karyotype high + very high 0.72 (0.27–1.92) 0.516
B-cell phenotype 1.36 (0.58–3.21) 0.484
Poor PSL response 1.52 (0.71–3.27) 0.284
CR by 2nd induction 1.64 (0.34–7.98) 0.538
SCT in 1st remission 1.01 (0.43–2.37) 0.980
Abbreviations: CI, confidence interval; CNS, central nervous system;
CR, complete remission; DFS, disease-free survival; PS, performance status;
PSL, prednisolone; SCT, stem cell transplantation; WBC, white blood cell.
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